Logo image
Autologous NeoHep Derived from Chronic Hepatitis B Virus Patients’ Blood Monocytes by Upregulation of c‐MET Signaling
Journal article   Open access   Peer reviewed

Autologous NeoHep Derived from Chronic Hepatitis B Virus Patients’ Blood Monocytes by Upregulation of c‐MET Signaling

Jashdeep Bhattacharjee, Barun Das, Disha Sharma, Preeti Sahay, Kshama Jain, Alaknanda Mishra, Srikanth Iyer, Puja Nagpal, Vinod Scaria, Perumal Nagarajan, …
Stem cells translational medicine, Vol.6(1), pp.174-186
01/2017
DOI: 10.5966/sctm.2015-0308
PMID: 28170202
url
https://doi.org/10.5966/sctm.2015-0308View
Published (Version of record) Open Access

Abstract

In view of the escalating need for autologous cell‐based therapy for treatment of liver diseases, a novel candidate has been explored in the present study. The monocytes isolated from hepatitis B surface antigen (HBsAg) nucleic acid test (NAT)‐positive (HNP) blood were differentiated to hepatocyte‐like cells (NeoHep) in vitro by a two‐step culture procedure. The excess neutrophils present in HNP blood were removed before setting up the culture. In the first step of culture, apoptotic cells were depleted and genes involved in hypoxia were induced, which was followed by the upregulation of genes involved in the c‐MET signaling pathway in the second step. The NeoHep were void of hepatitis B virus and showed expression of albumin, connexin 32, hepatocyte nuclear factor 4‐α, and functions such as albumin secretion and cytochrome P450 enzyme‐mediated detoxification of xenobiotics. The engraftment of NeoHep derived from HBsAg‐NAT‐positive blood monocytes in partially hepatectomized NOD.CB17‐Prkdcscid/J mice liver and the subsequent secretion of human albumin and clotting factor VII activity in serum make NeoHep a promising candidate for cell‐based therapy. Stem Cells Translational Medicine 2017;6:174–186
Tissue Engineering and Regenerative Medicine Translational s and Reviews

Details

Metrics

Logo image